Welcome to the e-CCO Library!

P689: Predictive transcriptional signatures associated to vedolizumab therapy response in patients with ulcerative colitis.
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Camba Gómez, M.(1)*;Arosa , L.(1);Calviño-Suárez, C.(2);Bastón-Rey, I.(2);Ferreiro-Iglesias, R.(2);Porto, M.(2);Nieto, L.(2);Domínguez-Muñoz, J.E.(2);Barreiro-de Acosta, M.(2);Conde-Aranda, J.(1);
Created: Friday, 14 July 2023, 11:12 AM
P689: The effect of nutritional therapy on bone mineral density and bone metabolism in paediatric Crohn’s disease
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

R. Lev-Tzion*1, T. Ben-Moshe1, G. Abitbol1, O. Ledder1,2, A. Levine3,4, S. Peleg5,6, P. Millman7, R. Shaoul6,8, H. Shamaly9, A. On10,11, M. Kori2,12, A. Assa13,14, S. Cohen4,15, E. Broide4,16, D. Turner1,2

Created: Friday, 22 February 2019, 9:41 AM
P689: UK Asians are prescribed vedolizumab earlier in disease history than Caucasians, but respond equally well to therapy
Year: 2018
Source: ECCO '18 Vienna
Authors:

H. Gordon1*, R. Gadhok1, A. Ibarra1,2, J.O. Lindsay1,3

Created: Thursday, 21 February 2019, 9:14 AM
P690 A propensity score weighted comparison of vedolizumab, adalimumab, and golimumab in patients with ulcerative colitis: Real-life data from the Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
Year: 2020
Source:

ECCO'20 Vienna

Authors:

F.S. Macaluso1, M. Ventimiglia1, W. Fries2, A. Viola2, M. Cappello3, B. Scrivo3, A. Magnano4, D. Pluchino4, S. Camilleri5, S. Garufi5, R. Di Mitri6, F. Mocciaro6, G. Magrì7, C. Ferracane7, M. Citrano8, F. Graziano8, C. Bertolami9, S. Renna1, R. Orlando1, G. Rizzuto1, M. Cottone1, A. Orlando1, Sicilian Network for Inflammatory Bowel Disease (SN-IBD)

Created: Thursday, 30 January 2020, 10:12 AM
P690: Ambient air quality does not affect disease course in inflammatory bowel disease – a population based risk factor analysis using geographic information systems
Year: 2017
Source: ECCO '17 Barcelona
Authors:

van den Heuvel T.*1, Bijnens E.2, Verhaegh B.1,3, Nawrot T.2, Zeegers M.4,5, Masclee A.1,3, Oostenbrug L.6, Romberg-Camps M.6, Jonkers D.1, Pierik M.1

Created: Wednesday, 20 February 2019, 10:36 AM
P690: Changes of intestinal microbiota in patients with inflammatory bowel diseases
Year: 2021
Source: ECCO'21 Virtual
Authors: Baryshnikova, N.(1);Uspenskiy, Y.(1);Suvorova, M.(2);Lyudyno , V.(2);Suvorov, A.(3);
Created: Wednesday, 2 June 2021, 4:12 PM
P690: Clinical and endoscopic outcomes of one year golimumab treatment in patients with active ulcerative colitis: A real-life observational study
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Berends1,2*, A. Strik2, J. Jansen3, N. de Boer4, J. Brandse4, G. D'Haens2, R. Mathôt1, M. Löwenberg2

Created: Thursday, 21 February 2019, 9:14 AM
P690: Comparative efficacy of vedolizumab and adalimumab as second-line therapy in ulcerative colitis patients previously treated with infliximab
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

A. Favale1, S. Onali*1, F. Caprioli2, D. Pugliese3, A. Armuzzi3, F. S. Macaluso4, A. Orlando4, A. Viola5, W. Fries5, G. Mocci6, F. Chicco7, P. Usai7, A. Rispo8, F. Castiglione8, E. Calabrese1, L. Biancone1, G. Monteleone1, M. C. Fantini1

Created: Friday, 22 February 2019, 9:41 AM
P690: Prolonged benefit of filgotinib in patients with Ulcerative Colitis in SELECTION
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Laharie, D.(1)*;Sturm, A.(2);Kobayashi, T.(3);Matsumoto, T.(4);Oortwijn, A.(5);Jamoul , C.(6);Faes, M.(6);de Haas, A.(7);Vermeire , S.(8);
Created: Friday, 14 July 2023, 11:12 AM
P690: Rates of IBD in New Zealand Māori population at Lakes District Health Board: low but increasing
Year: 2022
Source: ECCO'22
Authors: Qiu, M.(1);Patel, R.N.(2);Gearry, R.B.(3,4);
Created: Friday, 11 February 2022, 3:56 PM
P691 Corticosteroids usage in patients with inflammatory bowel disease: Results of a multi-national audit in Asia
Year: 2020
Source:

ECCO'20 Vienna

Authors:

D.H. Kim1, D.I. Park2, T. Kobayashi3, V. Ahuja4, B.I. Jang5, Q. Cao6, Y.J. Lee7, Z. Ran8, Clinical Research Committee of Asian Organization for Crohn’s and Colitis (AOCC)

Created: Thursday, 30 January 2020, 10:12 AM
P691: Cx601, a novel stem cell therapy for complex perianal fistulas in Crohn’s disease has rapid onset of clinical remission and low relapse rate by week 52
Year: 2018
Source: ECCO '18 Vienna
Authors:

D. García-Olmo1, J. Panés2*, N. Brayshaw3, M.P. Richard4, C. Agboton5

Created: Thursday, 21 February 2019, 9:14 AM
P691: Disparate care: rates of treat to target among patients with inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Haydek, J.(1);Oonk, A.(1);Cheng, D.(1);Ahmed, W.(1);Click, B.(1);Fennimore, B.(1);Gerich, M.(1);Hou, J.(2);Scott, F.(1)*;
Created: Friday, 14 July 2023, 11:12 AM
P691: Influence of ethnicity on the phenotype and clinical outcomes in Inflammatory Bowel Disease; comparison of a South American with a North American population.
Year: 2022
Source: ECCO'22
Authors: Pérez, T.(1);Pizarro, B.(2); Ascui, G.(3);Tobar, F.(4);Cerda-Villablanca, M.(5);Alvares, D.(6);Orellana, M.(7);De la Vega, A.(8);Canistra, M.(9);Cornejo, B.(9);Baez, P.(10);Silva, V.(2);Arriagada, E.(8);Estela, R.(2);Hernandez-Rocha, C.(11);Alvarez-Lobos, M.(12);Rivera-Nieves, J.(13);
Created: Friday, 11 February 2022, 3:56 PM
P691: Trends in diagnostic prevalence and treatment patterns of adult ulcerative colitis patients in the USA, 2007–2017
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

T. Hunter*1, A. Naegeli1, Y. Dong1, C. Choong1, D. Stefani-Hunyady1

Created: Friday, 22 February 2019, 9:41 AM
P691: UV exposure and skin type are more important than thiopurine exposure for non-melanoma skin cancer risk in IBD
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Wu Y.*1, Ghaly S.1, Kerr S.2, Krishnaprasad K.3, Prosser R.4, Jackson B.5, Hanigan K.3, Martins D.3, Mountifield R.4, Whiteman D.6, Bampton P.4, Gearry R.5, Radford-Smith G.3, Lawrance I.C.7,8

Created: Wednesday, 20 February 2019, 10:36 AM
P692 Exploring relationships between microbiome, faecal calprotectin and healthy eating index in patients with ulcerative colitis: Interim analyses of a randomised controlled trial
Year: 2020
Source:

ECCO'20 Vienna

Authors:

M. Raman1, L. Taylor1, A. Schick2, C. Ohland2, K. McCoy2, S. Kaur1, R. Panaccione1, R. Reimer3

Created: Thursday, 30 January 2020, 10:12 AM
P692: Clinical, therapeutic and evolutionary profile of fistulizing ano-perineal lesions in Crohn's disease
Year: 2022
Source: ECCO'22
Authors: Hassine, H.(1);KAHLAOUI, F.(1);Mtir, M.(1);Cherif, D.(1);Tlili, R.(1);Kchir, H.(1);Maamouri, N.(1);
Created: Friday, 11 February 2022, 3:56 PM
P692: Efficacy and safety of early biologic treatment of Crohn’s disease in adult and paediatric patients: A systematic review
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.-F. Colombel1*, R. Ungaro1, S. Aggarwal2, O. Topaloglu2, M. Skup3, W.-J. Lee3

Created: Thursday, 21 February 2019, 9:14 AM
P692: Inflammatory bowel diseases in Faroese-born Danish residents and their offspring. Further evidence of the dominant role of environmental factors in IBD development
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Hammer T.*1,2, Lophaven S.N.1, Rubek Nielsen K.3,4, von Euler-Chelpin M.C.1, Weihe P.2, Munkholm P.5, Burisch J.5, Lynge E.1

Created: Wednesday, 20 February 2019, 10:36 AM